Limits...
Management of chronic urticaria in Asia: 2010 AADV consensus guidelines.

Chow SK - Asia Pac Allergy (2012)

Bottom Line: If standard dosing is ineffective, increasing the dosage up to four-fold is recommended.For patients who do not respond to a four-fold increase in dosage of non-sedating H1-antihistamines, it is recommended that therapies such as H2-antihistamine, leukotriene antagonist, and cyclosporine A should be added to the antihistamine treatment.In the choice of second-line treatment, both their costs and risk/benefit profiles are the most important considerations.

View Article: PubMed Central - PubMed

Affiliation: The KL Skin Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, 59100, Malaysia.

ABSTRACT
This guideline is a result of a consensus reached during the 19th Asian-Australasian Regional Conference of Dermatology by the Asian Academy of Dermatology and Venereology Study Group in collaboration with the League of Asian Dermatological Societies in 2010. Urticaria has a profound impact on the quality of life in Asia and the need for effective treatment is required. In line with the EAACI/GA(2)LEN/EDF/WAO guideline for the management of urticaria the recommended first-line treatment is new generation, non-sedating H1-antihistamines. If standard dosing is ineffective, increasing the dosage up to four-fold is recommended. For patients who do not respond to a four-fold increase in dosage of non-sedating H1-antihistamines, it is recommended that therapies such as H2-antihistamine, leukotriene antagonist, and cyclosporine A should be added to the antihistamine treatment. In the choice of second-line treatment, both their costs and risk/benefit profiles are the most important considerations.

No MeSH data available.


Related in: MedlinePlus

Recommended treatment algorithm for chronic urticaria. (Taken from Fig. 1: EAACI/GA2LEN/EDF/WAO guideline: management of urticaria [1]).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3345329&req=5

Figure 1: Recommended treatment algorithm for chronic urticaria. (Taken from Fig. 1: EAACI/GA2LEN/EDF/WAO guideline: management of urticaria [1]).

Mentions: Depending upon the severity of the disease and response to various medicines, drug therapy can be considered at various levels as defined by four levels of therapy as discussed below (Fig. 1).


Management of chronic urticaria in Asia: 2010 AADV consensus guidelines.

Chow SK - Asia Pac Allergy (2012)

Recommended treatment algorithm for chronic urticaria. (Taken from Fig. 1: EAACI/GA2LEN/EDF/WAO guideline: management of urticaria [1]).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3345329&req=5

Figure 1: Recommended treatment algorithm for chronic urticaria. (Taken from Fig. 1: EAACI/GA2LEN/EDF/WAO guideline: management of urticaria [1]).
Mentions: Depending upon the severity of the disease and response to various medicines, drug therapy can be considered at various levels as defined by four levels of therapy as discussed below (Fig. 1).

Bottom Line: If standard dosing is ineffective, increasing the dosage up to four-fold is recommended.For patients who do not respond to a four-fold increase in dosage of non-sedating H1-antihistamines, it is recommended that therapies such as H2-antihistamine, leukotriene antagonist, and cyclosporine A should be added to the antihistamine treatment.In the choice of second-line treatment, both their costs and risk/benefit profiles are the most important considerations.

View Article: PubMed Central - PubMed

Affiliation: The KL Skin Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, 59100, Malaysia.

ABSTRACT
This guideline is a result of a consensus reached during the 19th Asian-Australasian Regional Conference of Dermatology by the Asian Academy of Dermatology and Venereology Study Group in collaboration with the League of Asian Dermatological Societies in 2010. Urticaria has a profound impact on the quality of life in Asia and the need for effective treatment is required. In line with the EAACI/GA(2)LEN/EDF/WAO guideline for the management of urticaria the recommended first-line treatment is new generation, non-sedating H1-antihistamines. If standard dosing is ineffective, increasing the dosage up to four-fold is recommended. For patients who do not respond to a four-fold increase in dosage of non-sedating H1-antihistamines, it is recommended that therapies such as H2-antihistamine, leukotriene antagonist, and cyclosporine A should be added to the antihistamine treatment. In the choice of second-line treatment, both their costs and risk/benefit profiles are the most important considerations.

No MeSH data available.


Related in: MedlinePlus